Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa

Bibliography

• FRIEDBERG CK: Diseases of the Heart. WB Saunders, Philadelphia, PA, (1966):781–785.
   Google Scholar
• DEWOOD MA, SPORES J, HENSLEY GR et al.: Coronary arteriographic findings in acute transmural myocar-dial infarction. Circulation (1983) 68:39–49.
   PubMed Web of Science ®Google Scholar
• HILLIS WS: The continuing debate: conservative or interventional therapy for unstable coronary disease. Am. J. Cardiol. (1997) 80 (5a):51E–54E.
   Google Scholar
• ANDERSON JL: Why does thrombolysis fail? Breaking through the reperfusion ceiling. Am. J. Cardiol. (1997) 80:1588–1590.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, THOMAS A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N.Engl. J. Med. (1984) 310:1147–1150.
   Google Scholar
• ••This is a elegant review of the fundamental role ofthrombosis in acute coronary ischaemia.
   Google Scholar
• FALK E: Unstable angina with fatal outcome. Dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation (1985) 71:799–708.
   Google Scholar
• ISIS-2. (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet (1988) 2:349–360.
   Google Scholar
• ••This is a land mark study that has had an enormous impacton the way we practice cardiology today.
   Google Scholar
• COLLINS R, PETO R, BAIGENT C et al.: Aspirin, heparin, and fibrinolytic therapy in suspected acute myocar-dial infarction. N Engl. J. Merl. (1997) 336:847–860.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1 9 9 6) 348:1329-1339.
   Google Scholar
• HAAS WK, EASTON JD, ADAMS HP JR et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of strokes in high risk patients. N Engl. J. Merl. (1989) 321:501–507.
   Google Scholar
• CAEN JP, CASTALDI PA, LECLERC JC et al.: Congenital bleeding disorders with long bleeding time and normal platelet count. 1. Glanzmann's thrombas-thenia. Am. J. Medicine (1966) 41:4–26.
   Google Scholar
• COLLER BS, SELIGSOHN U, PERETZ H et al.: Glanzmann's thrombasthenia: new insights from an historical perspective. Semin. Hematol (1994) 31:301–311.
   PubMed Web of Science ®Google Scholar
• NURDEN AT, CAEN JP: An abnormal platelet glycopro-tein pattern in three cases of Glanzmann's thrombas-thenia. Br. J. Haematol. (1974) 28:253–260.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, AGIN PP: Platelet membrane defects inGlanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J. Clinic Invest. (1977) 60:535–545.
   Web of Science ®Google Scholar
• KUNICKI TJ, PIDARD D, ROSA JP et al: The formation ofcalcium-dependent complexes of platelet membrane glycoproteins lib and Ma in solution as determined by crossed immunoelectrophoresis. Blood (1981) 58:268–278.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoproteinlib/Ilia receptors in cardiovascular medicine. N Engl. J. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, CHARO IF, PARISE LV et al.: The plateletmembrane glycoprotein Ilb/IIIa complex. Blood (1988) 71:831–843.
   PubMed Web of Science ®Google Scholar
• THE EPIC INVESTIGATORS. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high risk coronary angioplasty. N Engl. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• •This study was the first to demonstrate the potential of this group of agents for improving cardiovascular outcomes.
   Google Scholar
• TOPOL EJ, FERGUSON JJ, WEISMAN HF et al.: Long-termprotection from myocardial ischemic events in a randomized trial of brief Integrin 133 blockade with percutaneous coronary intervention. J. Am. Med. Assoc. (1997) 278:479–484.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoproteinHb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularisation. N Engl. J. Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, TCHENG JE, CALIFF RM et al.: Standardversus low dose weight adjusted heparin in patients treated with the platelet glycoprotein Ilb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularisation. The PROLOG investigators. Am. J. Cardiol (1997) 79:286–291.
   PubMed Web of Science ®Google Scholar
• THE CAPTURE INVESTIGATORS: Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• PYTELA R, PIERSCHBACHER MD, GINSBERG MH et al.: Platelet membrane glycoprotein Ilb/IIIa: a member of a family of Arg-Gly-Asp-specific adhesion receptors. Science (1986) 231:1559–1562.
   PubMed Web of Science ®Google Scholar
• ••This is a very well written introduction to the glycoproteinIIb/IIIa receptor. It establishes the importance of this receptor in thrombosis.
   Google Scholar
• MUSTARD JF, KINLOUGH-RATHBONE RL, PACKHAM MA:Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or Chymotrypsin. Blood (1979) 54:987–993.
   PubMed Web of Science ®Google Scholar
• DENNIS MS, HENZEL WJ, PITTI RM et al. Platelet glycoprotein Ilb/IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors.(ArgGlyAsp/fibrinogenreceptor/trigramin/ echistatin/kistrin). Proc. Natl. Acad. Sci. USA (1989) 87:2471–2475.
   Web of Science ®Google Scholar
• •Provides an interesting insight into the process of drug development from bench to bedside.
   Google Scholar
• SCARBOROUGH RM, NAUGHTON MA, TENG W: Design of potent and specific integrin antagonists with high specificity for glycoprotein Ilb/IIIa. J. Biol. Chem. (1993) 268:1066–1073.
   PubMed Web of Science ®Google Scholar
• •See reference [25] for annotation.
   Google Scholar
• CHARO IF, SCARBOROUGH RM, DU MEE CP et al.: Therapeutics I: Pharmacodynamics of the glycopro-tein Ilb/IIIa antagonist integrelin: Phase 1 clinical studies in normal healthy volunteers. Circulation (1992) 86 (Suppl. D:1–260.
   Google Scholar
• HANSON SR, KOTZE HF, SAVAGE B et al: Platelet interac-tions with Dacron grafts: a model of acute thrombosis in baboons. Arteriosclerosis (1985) 5:595–603.
   PubMedGoogle Scholar
• UTHOFF K, ZEHR KJ, GEERLING R et al.: Inhibition ofplatelet adhesion during cardiopulmonary by-pass reduces postoperative bleeding. Circulation (1994) 90:269–274.
   Web of Science ®Google Scholar
• TCHENG JE, HARRINGTON RA, KOTTKE-MARCHANT K etal.: Multicenter, randomized, double blind, placebo-controlled trial of the platelet integrin glycoprotein blocker Integrelin in elective coronary intervention. Circulation(1995) 91:2151–2157.
   Google Scholar
• HARRINGTON RA, KLIEMAN NS, KOTTKE-MARCHANT Ket al.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein Ilb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol. (1995) 76:1222–1227.
   Google Scholar
• PHILIPS DR, SCARBOROUGH RM: Clinical pharma-cology of eptifibatide. Am. J. Cardiol. (1997) 80(4a):11B–20B.
   Google Scholar
• The Physicians Desk Reference (1999).
   Google Scholar
• THE IMPACT II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complica-tions of percutaneous coronary intervention: IMPACT II. Lancet (1997) 349:1422–1428.
   PubMed Web of Science ®Google Scholar
• ••This study, together with the PURSUIT trial, wasfundamental in getting eptifibatide approved for the treatment of patients with acute coronary syndromes.
   Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein Ilb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl. J. Med. (1998) 339:436–443.
   PubMed Web of Science ®Google Scholar
• ••See reference [35] for annotation.
   Google Scholar
• OHMAN EM, KLEIMAN NS, GACIOCH G et al: Combined accelerated tissue-plasminogen activator and glycoprotein Ilb/IIIa integrin receptor blockade with Integrelin in acute myocardial infarction: results of a randomized, placebo-controlled dose ranging trial. Circulation (1997) 95:846–854.
   PubMed Web of Science ®Google Scholar
• RONNER E, VAN KERTEREN HA, ZIJNEN P et al.: Combined therapy with Streptokinase and Integrilin. J. Am. Coll Cardiol (1998) 31 (Suppl. a):191A.
   Google Scholar
• CHESEBRO JH, KNATTERUD G, ROBERTS R et al.: Thrombolysis in Myocardial Infarction (TIMO Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation (1987) 76:142–154.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, TENG W, ARFSTEN A et al: Effect of calcium on GP Ilb/IIIa interactions with Integrelin - enhanced GP IIb/IIIa binding and inhibition of platelet aggrega-tion by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circula-tion (1997) 96:1488–1494.
   PubMed Web of Science ®Google Scholar
• TCHENG JE: Glycoprotein IIb/IIIa inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. J. Cardiol (1996) 78 (Suppl. 3a):35–40.
   Google Scholar
• TCHENG JE, THEL MC, JENNINGS L et al.: Platelet glycoprotein Ilb/IIIa receptor blockade with high dose IntegrilinTM in coronary intervention. Results of the PRIDE Study. Eur. Heart J. (1997) 18:3615. James E Tchengt & J Conor O'Shea tAuthor for correspondence Duke Clinical Research Institute Box 3275, Duke University Medical Center, Durham, NC 27710, USA Tel.: +1 919 668 8796; Fax:+1 919 668 0355; Email: [email protected]
   Google Scholar